Nearly two decades later, studies showed that this response was due to a unique PML-RARα fusion oncogene in >95% of APL cases that degrades upon binding to atRA, leading to the differentiation of leukemic blasts.3 The gene discussed is RARA; the disease is acute promyelocytic leukemia.